Pilocarpine is conventionally applied as eyedrops in aqueous solutions of various concentrations. Alternative technologies for drug delivery have been developed (solutions in castor oil, Ocuserts, and others), but these have not found wide clinical application. A novel ophthalmic delivery system (NODS) has recently been designed to deliver a precise amount of the drug to the eye. The medication is incorporated into a water-soluble polyvinyl alcohol (PVA) film which detaches from the rest of the device (a stiffened paper strip handle) when placed in the lower conjunctival sac (Fig. 1) . The medicated film (length 4 mm, width 6-3 mm, thickness 20 [im, volume 0-5 [d) dissolves in the tear fluid releasing the medication. The overall length is 55 mm, the whole device being of similar size to a Fluoret. The NODS contains no preservative and is sterilised by gamma radiation.
Pilocarpine is conventionally applied as eyedrops in aqueous solutions of various concentrations. Alternative technologies for drug delivery have been developed (solutions in castor oil, Ocuserts, and others), but these have not found wide clinical application. A novel ophthalmic delivery system (NODS) has recently been designed to deliver a precise amount of the drug to the eye. The medication is incorporated into a water-soluble polyvinyl alcohol (PVA) film which detaches from the rest of the device (a stiffened paper strip handle) when placed in the lower conjunctival sac (Fig. 1) . The medicated film (length 4 In each subject graphs of the log dose pilocarpineresponse relationships for the NODS formulations were plotted and the equivalent dose for the eyedrop formulation calculated by interpolation. Mean values, standard errors of mean, and 95% confidence intervals for these estimates were calculated by standard methods.
Results
Pilocarpine constricted the pupil in all doses studied. The time course of this constriction is shown in Fig. 2 close or equal to a maximum (Fig. 3) . (X2=19¢014, p<O0OOl). In only one subject on one occasion did mild discomfort persist for 20 min. Stinging and eye watering occurred equally with the two types of formulation.
Intense miosis in response to the treatments was associated with eye or brow ache on the treated side during the first two hours after instillation. Headache, severe enough to require medication with paracetamol, occurred in two subjects thereafter. These responses were dose related and not associated with a particular formulation.
Discussion
The quantity of drug applied to the eye from conventional eyedrops is necessarily high because of the low bioavailability from this route. At least 80% of the volume of an administered eyedrop drains rapidly through the nasolacrimal duct, allowing for subsequent systemic absorption. 
